Targeted inhibition of ATR or CHEK1 reverses radioresistance in oral squamous cell carcinoma cells with distal chromosome arm 11q loss

Genes Chromosomes and Cancer

Volumn 53, Issue 2, 2014, Pages 129-143

  Sankunny, Madhav ^a,b   Parikh, Rahul A ^b,c   Lewis, Dale W ^a   Gooding, William E ^b   Saunders, William S ^b,d   Gollin, Susanne M ^a,b,c  

^a UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

^b UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

^c UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATR CHEK1 PATHWAY; SIGNAL TRANSDUCING ADAPTOR PROTEIN; SMALL INTERFERING RNA; UNCLASSIFIED DRUG;

ARTICLE; CANCER CELL; CANCER CELL CULTURE; CANCER RESISTANCE; CANCER SURVIVAL; CHROMOSOME 11Q; CHROMOSOME ANALYSIS; CHROMOSOME ARM; CHROMOSOME LOSS; CLONOGENIC ASSAY; COPY NUMBER VARIATION; DISEASE SPECIFIC SURVIVAL; ENZYME INHIBITION; G2 PHASE CELL CYCLE CHECKPOINT; GENE AMPLIFICATION; GENE SILENCING; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; IONIZING RADIATION; MOUTH SQUAMOUS CELL CARCINOMA; PRIORITY JOURNAL; RADIOSENSITIVITY; RNA INTERFERENCE;

ATAXIA TELANGIECTASIA MUTATED PROTEINS; CARCINOMA, SQUAMOUS CELL; CELL LINE, TUMOR; CHROMOSOME DELETION; CHROMOSOME SEGREGATION; CHROMOSOMES, HUMAN, PAIR 11; DNA DAMAGE; GENE KNOCKDOWN TECHNIQUES; HUMANS; M PHASE CELL CYCLE CHECKPOINTS; MOUTH NEOPLASMS; PROTEIN KINASE INHIBITORS; PROTEIN KINASES; RADIATION TOLERANCE; SIGNAL TRANSDUCTION; UP-REGULATION;

EID: 84890070266     PISSN: 10452257     EISSN: 10982264     Source Type: Journal    
DOI: 10.1002/gcc.22125     Document Type: Article

References (82)

1. Abraham RT. 2004. PI 3-kinase related kinases: 'Big' players in stress-induced signaling pathways. DNA Repair 3:883-887.
2. Adams KE, Medhurst AL, Dart DA, Lakin ND. 2006. Recruitment of ATR to sites of ionising radiation-induced DNA damage requires ATM and components of the MRN protein complex. Oncogene 25:3894-3904.
3. Akervall JA, Jin Y, Wennerberg JP, Zatterstrom UK, Kjellen E, Mertens F, Willen R, Mandahl N, Heim S, Mitelman F. 1995. Chromosomal abnormalities involving 11q13 are associated with poor prognosis in patients with squamous cell carcinoma of the head and neck. Cancer 76:853-859.
4. Akervall JA, Michalides RJ, Mineta H, Balm A, Borg A, Dictor MR, Jin Y, Loftus B, Mertens F, Wennerberg JP. 1997. Amplification of cyclin D1 in squamous cell carcinoma of the head and neck and the prognostic value of chromosomal abnormalities and cyclin D1 overexpression. Cancer 79:380-389.
5. Albertson DG. 2006. Gene amplification in cancer. Trends Genet 22:447-455.
6. Ambatipudi S, Gerstung M, Gowda R, Pai P, Borges AM, Schaffer AA, Beerenwinkel N, Mahimkar MB. 2011. Genomic profiling of advanced-stage oral cancers reveals chromosome 11q alterations as markers of poor clinical outcome. PLoS One 6:e17250.
7. Bakkenist CJ, Kastan MB. 2003. DNA damage activates ATM through intermolecular autophosphorylation and dimer dissociation. Nature 421:499-506.
8. Baskaran R, Wood LD, Whitaker LL, Canman CE, Morgan SE, Xu Y, Barlow C, Baltimore D, Wynshaw-Boris A, Kastan MB, Wang JY. 1997. Ataxia telangiectasia mutant protein activates c-Abl tyrosine kinase in response to ionizing radiation. Nature 387:516-519.
9. Bennett CN, Tomlinson CC, Michalowski AM, Chu IM, Luger D, Mittereder LR, Aprelikova O, Shou J, Piwinica-Worms H, Caplen NJ, Hollingshead MG, Green JE. 2012. Cross-species genomic and functional analyses identify a combination therapy using a CHK1 inhibitor and a ribonucleotide reductase inhibitor to treat triple-negative breast cancer. Breast Cancer Res 14:R109.
10. Beroukhim R, Mermel CH, Porter D, Wei G, Raychaudhuri S, Donovan J, Barretina J, Boehm JS, Dobson J, Urashima M, Mc Henry KT, Pinchback RM, Ligon AH, Cho YJ, Haery L, Greulich H, Reich M, Winckler W, Lawrence MS, Weir BA, Tanaka KE, Chiang DY, Bass AJ, Loo A, Hoffman C, Prensner J, Liefeld T, Gao Q, Yecies D, Signoretti S, Maher E, Kaye FJ, Sasaki H, Tepper JE, Fletcher JA, Tabernero J, Baselga J, Tsao MS, Demichelis F, Rubin MA, Janne PA, Daly MJ, Nucera C, Levine RL, Ebert BL, Gabriel S, Rustgi AK, Antonescu CR, Ladanyi M, Letai A, Garraway LA, Loda M, Beer DG, True LD, Okamoto A, Pomeroy SL, Singer S, Golub TR, Lander ES, Getz G, Sellers WR, Meyerson M. 2010. The landscape of somatic copy-number alteration across human cancers. Nature 463:899-905.
11. Blasina A, Hallin J, Chen E, Arango ME, Kraynov E, Register J, Grant S, Ninkovic S, Chen P, Nichols T, O'Connor P, Anderes K. 2008. Breaching the DNA damage checkpoint via PF-00477736, a novel small-molecule inhibitor of checkpoint kinase 1. Mol Cancer Ther 7:2394-2404.
12. Borst GR, McLaughlin M, Kyula JN, Neijenhuis S, Khan A, Good J, Zaidi S, Powell NG, Meier P, Collins I, Garrett MD, Verheij M, Harrington KJ. 2012. Targeted Radiosensitization by the Chk1 Inhibitor SAR-020106. Int J Radiat Oncol Biol Phys 85:1110-1118.
13. Bray F, Ren JS, Masuyer E, Ferlay J. 2013. Global estimates of cancer prevalence for 27 sites in the adult population in 2008. Int J Cancer 132:1133-1145.
14. Busby EC, Leistritz DF, Abraham RT, Karnitz LM, Sarkaria JN. 2000. The radiosensitizing agent 7-hydroxystaurosporine (UCN-01) inhibits the DNA damage checkpoint kinase hChk1. Cancer Res 60:2108-2112.
15. Byun TS, Pacek M, Yee MC, Walter JC, Cimprich KA. 2005. Functional uncoupling of MCM helicase and DNA polymerase activities activates the ATR-dependent checkpoint. Genes Dev 19:1040-1052.
16. Choi S, Gamper AM, White JS, Bakkenist CJ. 2010. Inhibition of ATM kinase activity does not phenocopy ATM protein disruption: Implications for the clinical utility of ATM kinase inhibitors. Cell Cycle 9:4052-4057.
17. Clark ES, Brown B, Whigham AS, Kochaishvili A, Yarbrough WG, Weaver AM. 2009. Aggressiveness of HNSCC tumors depends on expression levels of cortactin, a gene in the 11q13 amplicon. Oncogene 28:431-444.
18. Cortez D, Guntuku S, Qin J, Elledge SJ. 2001. ATR and ATRIP: Partners in checkpoint signaling. Science 294:1713-1716.
19. Cuadrado M, Martinez-Pastor B, Murga M, Toledo LI, Gutierrez-Martinez P, Lopez E, Fernandez-Capetillo O. 2006. ATM regulates ATR chromatin loading in response to DNA double-strand breaks. J Exp Med 203:297-303.
20. Desantis C, Naishadham D, Jemal A. 2013. Cancer statistics for African Americans, 2013. CA Cancer J Clin 63:151-166.
21. Dickson MA, Hahn WC, Ino Y, Ronfard V, Wu JY, Weinberg RA, Louis DN, Li FP, Rheinwald JG. 2000. Human keratinocytes that express hTERT and also bypass a p16(INK4a)-enforced mechanism that limits life span become immortal yet retain normal growth and differentiation characteristics. Mol Cell Biol 20:1436-1447.
22. Edelmann J, Holzmann K, Miller F, Winkler D, Buhler A, Zenz T, Bullinger L, Kuhn MW, Gerhardinger A, Bloehdorn J, Radtke I, Su X, Ma J, Pounds S, Hallek M, Lichter P, Korbel J, Busch R, Mertens D, Downing JR, Stilgenbauer S, Dohner H. 2012. High-resolution genomic profiling of chronic lymphocytic leukemia reveals new recurrent genomic alterations. Blood 120:4783-4794.
23. Fenech M, Kirsch-Volders M, Natarajan AT, Surralles J, Crott JW, Parry J, Norppa H, Eastmond DA, Tucker JD, Thomas P. 2011. Molecular mechanisms of micronucleus, nucleoplasmic bridge and nuclear bud formation in mammalian and human cells. Mutagenesis 26:125-132.
24. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. 2010. GLOBOCAN 2008 v1.2. cancer Incidence and Mortality Worldwide: IARC CancerBase No.10. Cancer IAFRO. Lyon, France: International Agency for Research on Cancer.
25. Fernandez-Capetillo O, Lee A, Nussenzweig M, Nussenzweig A. 2004. H2AX: the histone guardian of the genome. DNA Repair 3:959-967.
26. Ferrao PT, Bukczynska EP, Johnstone RW, McArthur GA. 2012. Efficacy of CHK inhibitors as single agents in MYC-driven lymphoma cells. Oncogene 31:1661-1672.
27. Fracchiolla NS, Pruneri G, Pignataro L, Carboni N, Capaccio P, Boletini A, Buffa R, Neri A. 1997. Molecular and immunohistochemical analysis of the bcl-1/cyclin D1 gene in laryngeal squamous cell carcinomas: correlation of protein expression with lymph node metastases and advanced clinical stage. Cancer 79:1114-1121.
28. Fragkos M, Beard P. 2011. Mitotic catastrophe occurs in the absence of apoptosis in p53-null cells with a defective G1 checkpoint. PLoS One 6:e22946.
29. Gatei M, Sloper K, Sorensen C, Syljuasen R, Falck J, Hobson K, Savage K, Lukas J, Zhou BB, Bartek J, Khanna KK. 2003. Ataxia-telangiectasia-mutated (ATM) and NBS1-dependent phosphorylation of Chk1 on Ser-317 in response to ionizing radiation. J Biol Chem 278:14806-14811.
30. George RE, Attiyeh EF, Li S, Moreau LA, Neuberg D, Li C, Fox EA, Meyerson M, Diller L, Fortina P, Look AT, Maris JM. 2007. Genome-wide analysis of neuroblastomas using high-density single nucleotide polymorphism arrays. PLoS One 2:e255.
31. Gibcus JH, Kok K, Menkema L, Hermsen MA, Mastik M, Kluin PM, van der Wal JE, Schuuring E. 2007. High-resolution mapping identifies a commonly amplified 11q13.3 region containing multiple genes flanked by segmental duplications. Hum Genet 121:187-201.
32. Gollin SM. 2001. Chromosomal alterations in squamous cell carcinomas of the head and neck: window to the biology of disease. Head Neck 23:238-253.
33. Graves PR, Yu L, Schwarz JK, Gales J, Sausville EA, O'Connor PM, Piwnica-Worms H. 2000. The Chk1 protein kinase and the Cdc25C regulatory pathways are targets of the anticancer agent UCN-01. J Biol Chem 275:5600-5605.
34. Ha PK, Califano JA, 3rd. 2002. The molecular biology of laryngeal cancer. Otolaryngol Clin North Am 35:993-1012.
35. Harnden DG. 1994. The nature of ataxia-telangiectasia: problems and perspectives. Int J Radiat Biol 66:S13-19.
36. Henson BJ, Bhattacharjee S, O'Dee DM, Feingold E, Gollin SM. 2009. Decreased expression of miR-125b and miR-100 in oral cancer cells contributes to malignancy. Genes Chromosomes Cancer 48:569-582.
37. Heron M, Hoyert DL, Murphy SL, Xu J, Kochanek KD, Tejada-Vera B. 2009. Deaths: final data for 2006. Natl Vital Stat Rep 57:1-134.
38. Huang X, Gollin SM, Raja S, Godfrey TE. 2002. High-resolution mapping of the 11q13 amplicon and identification of a gene, TAOS1, that is amplified and overexpressed in oral cancer cells. Proc Natl Acad Sci USA 99:11369-11374.
39. Inoue Y, Kitagawa M, Taya Y. 2007. Phosphorylation of pRB at Ser612 by Chk1/2 leads to a complex between pRB and E2F-1 after DNA damage. EMBO J 26:2083-2093.
40. Jares P, Fernandez PL, Campo E, Nadal A, Bosch F, Aiza G, Nayach I, Traserra J, Cardesa A. 1994. PRAD-1/cyclin D1 gene amplification correlates with messenger RNA overexpression and tumor progression in human laryngeal carcinomas. Cancer Res 54:4813-4817.
41. Jiang K, Pereira E, Maxfield M, Russell B, Goudelock DM, Sanchez Y. 2003. Regulation of Chk1 includes chromatin association and 14-3-3 binding following phosphorylation on Ser-345. J Biol Chem 278:25207-25217.
42. Jin C, Jin Y, Gisselsson D, Wennerberg J, Wah TS, Stromback B, Kwong YL, Mertens F. 2006. Molecular cytogenetic characterization of the 11q13 amplicon in head and neck squamous cell carcinoma. Cytogenet Genome Res 115:99-106.
43. Jin Y, Hoglund M, Jin C, Martins C, Wennerberg J, Akervall J, Mandahl N, Mitelman F, Mertens F. 1998. FISH characterization of head and neck carcinomas reveals that amplification of band 11q13 is associated with deletion of distal 11q. Genes Chromosomes Cancer 22:312-320.
44. Karp JE, Thomas BM, Greer JM, Sorge C, Gore SD, Pratz KW, Smith BD, Flatten KS, Peterson K, Schneider P, Mackey K, Freshwater T, Levis MJ, McDevitt MA, Carraway HE, Gladstone DE, Showel MM, Loechner S, Parry DA, Horowitz JA, Isaacs R, Kaufmann SH. 2012. Phase I and pharmacologic trial of cytosine arabinoside with the selective checkpoint 1 inhibitor Sch 900776 in refractory acute leukemias. Clin Cancer Res 18:6723-6731.
45. Keith CT, Schreiber SL. 1995. PIK-related kinases: DNA repair, recombination, and cell cycle checkpoints. Science 270:50-51.
46. Khanna KK, Jackson SP. 2001. DNA double-strand breaks: Signaling, repair and the cancer connection. Nat Genet 27:247-254.
47. Lavin MF, Shiloh Y. 1997. The genetic defect in ataxia-telangiectasia. Annu Rev Immunol 15:177-202.
48. Martin C, Reshmi S, Ried T, Gottberg W, Wilson J, Reddy J, Khanna P, Johnson J, Myers E, Gollin S. 2008. Chromosomal imbalances in oral squamous cell carcinoma: examination of 31 cell lines and review of the literature. Oral Oncol 44:369-382.
49. Mermel CH, Schumacher SE, Hill B, Meyerson ML, Beroukhim R, Getz G. 2011. GISTIC2.0 facilitates sensitive and confident localization of the targets of focal somatic copy-number alteration in human cancers. Genome Biol 12:R41.
50. Michalides R, van Veelen N, Hart A, Loftus B, Wientjens E, Balm A. 1995. Overexpression of cyclin D1 correlates with recurrence in a group of forty-seven operable squamous cell carcinomas of the head and neck. Cancer Res 55:975-978.
51. Michalides RJ, van Veelen NM, Kristel PM, Hart AA, Loftus BM, Hilgers FJ, Balm AJ. 1997. Overexpression of cyclin D1 indicates a poor prognosis in squamous cell carcinoma of the head and neck. Arch Otolaryngol Head Neck Surg 123:497-502.
52. Mineta H, Miura K, Takebayashi S, Ueda Y, Misawa K, Harada H, Wennerberg J, Dictor M. 2000. Cyclin D1 overexpression correlates with poor prognosis in patients with tongue squamous cell carcinoma. Oral oncology 36:194-198.
53. Miyamoto R, Uzawa N, Nagaoka S, Hirata Y, Amagasa T. 2003. Prognostic significance of cyclin D1 amplification and overexpression in oral squamous cell carcinomas. Oral oncology 39:610-618.
54. Myers JS, Cortez D. 2006. Rapid activation of ATR by ionizing radiation requires ATM and Mre11. J Biol Chem 281:9346-9350.
55. Niida H, Katsuno Y, Banerjee B, Hande MP, Nakanishi M. 2007. Specific role of Chk1 phosphorylations in cell survival and checkpoint activation. Mol Cell Biol 27:2572-2581.
56. Origanti S, Cai SR, Munir AZ, White LS, Piwnica-Worms H. 2013. Synthetic lethality of Chk1 inhibition combined with p53 and/or p21 loss during a DNA damage response in normal and tumor cells. Oncogene 32:577-588.
57. Pandita TK, Westphal CH, Anger M, Sawant SG, Geard CR, Pandita RK, Scherthan H. 1999. Atm inactivation results in aberrant telomere clustering during meiotic prophase. Mol Cell Biol 19:5096-5105.
58. Parikh RA, White JS, Huang X, Schoppy DW, Baysal BE, Baskaran R, Bakkenist CJ, Saunders WS, Hsu LC, Romkes M, Gollin SM. 2007. Loss of distal 11q is associated with DNA repair deficiency and reduced sensitivity to ionizing radiation in head and neck squamous cell carcinoma. Genes Chromosomes Cancer 46:761-775.
59. Reshmi SC, Roychoudhury S, Yu Z, Feingold E, Potter D, Saunders WS, Gollin SM. 2007. Inverted duplication pattern in anaphase bridges confirms the breakage-fusion-bridge (BFB) cycle model for 11q13 amplification. Cytogenet Genome Res 116:46-52.
60. Savitsky K, Bar-Shira A, Gilad S, Rotman G, Ziv Y, Vanagaite L, Tagle DA, Smith S, Uziel T, Sfez S, Ashkenazi M, Pecker I, Frydman M, Harnik R, Patanjali SR, Simmons A, Clines GA, Sartiel A, Gatti RA, Chessa L, Sanal O, Lavin MF, Jaspers NG, Taylor AM, Arlett CF, Miki T, Weissman SM, Lovett M, Collins FS, Shiloh Y. 1995. A single ataxia telangiectasia gene with a product similar to PI-3 kinase. Science 268:1749-1753.
61. Schenk EL, Koh BD, Flatten KS, Peterson KL, Parry D, Hess AD, Smith BD, Karp JE, Karnitz LM, Kaufmann SH. 2012. Effects of selective checkpoint kinase 1 inhibition on cytarabine cytotoxicity in acute myelogenous leukemia cells in vitro. Clin Cancer Res 18:5364-5373.
62. Schraml P, Kononen J, Bubendorf L, Moch H, Bissig H, Nocito A, Mihatsch MJ, Kallioniemi OP, Sauter G. 1999. Tissue microarrays for gene amplification surveys in many different tumor types. Clin Cancer Res 5:1966-1975.
63. Shaheen M, Allen C, Nickoloff JA, Hromas R. 2011. Synthetic lethality: exploiting the addiction of cancer to DNA repair. Blood 117:6074-6082.
64. Shiloh Y. 2003. ATM and related protein kinases: Safeguarding genome integrity. Nat Rev Cancer 3:155-168.
65. Shuster MI, Han L, Le Beau MM, Davis E, Sawicki M, Lese CM, Park NH, Colicelli J, Gollin SM. 2000. A consistent pattern of RIN1 rearrangements in oral squamous cell carcinoma cell lines supports a breakage-fusion-bridge cycle model for 11q13 amplification. Genes Chromosomes Cancer 28:153-163.
66. Siegel R, Naishadham D, Jemal A. 2013. Cancer statistics, 2013. CA Cancer J Clin 63:11-30.
67. Stracker TH, Theunissen JW, Morales M, Petrini JH. 2004. The Mre11 complex and the metabolism of chromosome breaks: The importance of communicating and holding things together. DNA Repair 3:845-854.
68. Stucki M, Clapperton JA, Mohammad D, Yaffe MB, Smerdon SJ, Jackson SP. 2005. MDC1 directly binds phosphorylated histone H2AX to regulate cellular responses to DNA double-strand breaks. Cell 123:1213-1226.
69. Swarts DR, Claessen SM, Jonkers YM, van Suylen RJ, Dingemans AM, de Herder WW, de Krijger RR, Smit EF, Thunnissen FB, Seldenrijk CA, Vink A, Perren A, Ramaekers FC, Speel EJ. 2011. Deletions of 11q22.3-q25 are associated with atypical lung carcinoids and poor clinical outcome. Am J Pathol 179:1129-1137.
70. Tao Y, Leteur C, Yang C, Zhang P, Castedo M, Pierre A, Golsteyn RM, Bourhis J, Kroemer G, Deutsch E. 2009. Radiosensitization by Chir-124, a selective CHK1 inhibitor: effects of p53 and cell cycle checkpoints. Cell Cycle 8:1196-1205.
71. Uto K, Inoue D, Shimuta K, Nakajo N, Sagata N. 2004. Chk1, but not Chk2, inhibits Cdc25 phosphatases by a novel common mechanism. EMBO J 23:3386-3396.
72. Verlinden L, Vanden Bempt I, Eelen G, Drijkoningen M, Verlinden I, Marchal K, De Wolf-Peeters C, Christiaens MR, Michiels L, Bouillon R, Verstuyf A. 2007. The E2F-regulated gene Chk1 is highly expressed in triple-negative estrogen receptor /progesterone receptor /HER-2 breast carcinomas. Cancer Res 67:6574-6581.
73. Wang H, Powell SN, Iliakis G, Wang Y. 2004. ATR affecting cell radiosensitivity is dependent on homologous recombination repair but independent of nonhomologous end joining. Cancer Res 64:7139-7143.
74. Wang H, Hu B, Liu R, Wang Y. 2005. CHK1 affecting cell radiosensitivity is independent of non-homologous end joining. Cell Cycle 4:300-303.
75. Wang J, Han X, Zhang Y. 2012. Autoregulatory mechanisms of phosphorylation of checkpoint kinase 1. Cancer Res 72:3786-3794.
76. Wang X, Khadpe J, Hu B, Iliakis G, Wang Y. 2003. An overactivated ATR/CHK1 pathway is responsible for the prolonged G2 accumulation in irradiated AT cells. J Biol Chem 278:30869-30874.
77. White JS, Weissfeld JL, Ragin CC, Rossie KM, Martin CL, Shuster M, Ishwad CS, Law JC, Myers EN, Johnson JT, Gollin SM. 2007. The influence of clinical and demographic risk factors on the establishment of head and neck squamous cell carcinoma cell lines. Oral Oncol 43:701-712.
78. Wreesmann VB, Shi W, Thaler HT, Poluri A, Kraus DH, Pfister D, Shaha AR, Shah JP, Rao PH, Singh B. 2004a. Identification of novel prognosticators of outcome in squamous cell carcinoma of the head and neck. J Clin Oncol 22:3965-3972.
79. Wreesmann VB, Wang D, Goberdhan A, Prasad M, Ngai I, Schnaser EA, Sacks PG, Singh B. 2004b. Genetic abnormalities associated with nodal metastasis in head and neck cancer. Head & Neck 26:10-15.
80. Wu W, Bi C, Bence AK, Um SL, Yan B, Starling JJ, Marshall MS, Beckmann RP. 2012. Antitumor activity of Chk1 inhibitor LY2606368 as a single agent in SW1990 human pancreas orthotopic tumor model. Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research, 2012 Mar 31-Apr 4, Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2012;72(8 Suppl):Abstract nr 1776.
81. Zhang SY, Liu SC, Johnson DG, Klein-Szanto AJ. 2000. E2F-1 gene transfer enhances invasiveness of human head and neck carcinoma cell lines. Cancer Res 60:5972-5976.
82. Zou L, Elledge SJ. 2003. Sensing DNA damage through ATRIP recognition of RPA-ssDNA complexes. Science 300:1542-1548.